Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 01 04:00PM ET
18.05
Dollar change
+0.42
Percentage change
2.38
%
IndexRUT P/E- EPS (ttm)-1.02 Insider Own69.33% Shs Outstand151.95M Perf Week-6.38%
Market Cap2.76B Forward P/E- EPS next Y-2.61 Insider Trans7.40% Shs Float46.84M Perf Month21.14%
Income-155.34M PEG- EPS next Q-0.76 Inst Own15.33% Short Float10.68% Perf Quarter48.80%
Sales0.00M P/S- EPS this Y-94.73% Inst Trans- Short Ratio17.06 Perf Half Y-
Book/sh3.36 P/B5.38 EPS next Y-11.70% ROA-31.87% Short Interest5.00M Perf Year-
Cash/sh3.34 P/C5.41 EPS next 5Y- ROE-33.85% 52W Range9.35 - 19.90 Perf YTD5.87%
Dividend Est.- P/FCF- EPS past 5Y- ROI-30.14% 52W High-9.30% Beta-
Dividend TTM- Quick Ratio18.05 Sales past 5Y0.00% Gross Margin- 52W Low93.05% ATR (14)1.27
Dividend Ex-Date- Current Ratio18.05 EPS Y/Y TTM- Oper. Margin0.00% RSI (14)54.53 Volatility7.59% 7.76%
Employees- Debt/Eq0.01 Sales Y/Y TTM- Profit Margin- Recom1.33 Target Price21.29
Option/ShortYes / Yes LT Debt/Eq0.01 EPS Q/Q-79.85% Payout- Rel Volume1.44 Prev Close17.63
Sales Surprise- EPS Surprise-228.44% Sales Q/Q- EarningsNov 01 BMO Avg Volume293.02K Price18.05
SMA201.94% SMA509.84% SMA20030.75% Trades Volume422,976 Change2.38%
Date Action Analyst Rating Change Price Target Change
Dec-12-23Initiated Deutsche Bank Hold $13
Oct-10-23Initiated William Blair Outperform $26
Oct-10-23Initiated Stifel Buy $26
Oct-10-23Initiated RBC Capital Mkts Outperform $24
Oct-10-23Initiated JP Morgan Overweight $21
Oct-10-23Initiated Guggenheim Buy $22
Oct-10-23Initiated BofA Securities Buy $18
Jan-22-24 07:00AM
Jan-10-24 08:32AM
Jan-02-24 07:00AM
Dec-17-23 12:35PM
Dec-12-23 07:00AM
07:00AM Loading…
Nov-27-23 07:00AM
Nov-01-23 07:00AM
Oct-30-23 07:00AM
Oct-10-23 07:00AM
Sep-28-23 07:54PM
Sep-27-23 06:50PM
Sep-18-23 12:35PM
Sep-14-23 08:49PM
Neumora Therapeutics, Inc. is a clinical-stage biotechnology company. It offers a precision medicine approach for brain diseases through the integration of data science and neuroscience. The firm focuses on advancing medicines for therapeutically relevant targets implicated in CNS diseases, targeting novel mechanisms of action with best-in-class pharmacology. The company was founded by Paul L. Berns, Carol Suh and Mike Poole in November 2019 and is headquartered in Watertown, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
ARCH Venture Partners XII, LLC10% OwnerNov 14Buy11.983,35740,2174,131,207Nov 15 06:54 PM
Burow KristinaDirectorNov 14Buy11.983,35740,2174,131,207Nov 15 06:55 PM
Burow KristinaDirectorNov 13Buy11.7531,653371,9234,127,850Nov 15 06:55 PM
ARCH Venture Partners XII, LLC10% OwnerNov 13Buy11.7531,653371,9234,127,850Nov 15 06:54 PM
Burow KristinaDirectorNov 10Buy11.4917,275198,4814,096,197Nov 13 07:01 PM
ARCH Venture Partners XII, LLC10% OwnerNov 10Buy11.4917,275198,4814,096,197Nov 13 07:00 PM
ARCH Venture Partners XII, LLC10% OwnerNov 09Buy10.5331,079327,2624,078,922Nov 13 07:00 PM
Burow KristinaDirectorNov 09Buy10.5331,079327,2624,078,922Nov 13 07:01 PM
Burow KristinaDirectorNov 08Buy11.0392,2511,017,8214,047,843Nov 13 07:01 PM
ARCH Venture Partners XII, LLC10% OwnerNov 08Buy11.0392,2511,017,8214,047,843Nov 13 07:00 PM
ARCH Venture Partners XII, LLC10% OwnerNov 07Buy11.5030,192347,2083,955,592Nov 07 06:59 PM
Burow KristinaDirectorNov 07Buy11.5030,192347,2083,955,592Nov 07 07:00 PM
Burow KristinaDirectorNov 06Buy11.5543,082497,5973,925,400Nov 07 07:00 PM
ARCH Venture Partners XII, LLC10% OwnerNov 06Buy11.5543,082497,5973,925,400Nov 07 06:59 PM
ARCH Venture Partners XII, LLC10% OwnerNov 03Buy11.3822,420255,1403,882,318Nov 07 06:59 PM
Burow KristinaDirectorNov 03Buy11.3822,420255,1403,882,318Nov 07 07:00 PM
ARCH Venture Partners XII, LLC10% OwnerSep 29Buy13.9834,560483,1493,859,898Sep 29 06:53 PM
Burow KristinaDirectorSep 29Buy13.9834,560483,1493,859,898Sep 29 06:55 PM
Burow KristinaDirectorSep 28Buy13.4441,951563,6993,825,338Sep 29 06:55 PM
ARCH Venture Partners XII, LLC10% OwnerSep 28Buy13.4441,951563,6993,825,338Sep 29 06:53 PM
Burow KristinaDirectorSep 27Buy12.3124,504301,6443,783,387Sep 27 08:19 PM
ARCH Venture Partners XII, LLC10% OwnerSep 27Buy12.3124,504301,6443,783,387Sep 27 08:18 PM
ARCH Venture Partners XII, LLC10% OwnerSep 26Buy11.7334,000398,8203,758,883Sep 27 08:18 PM
Burow KristinaDirectorSep 26Buy11.7334,000398,8203,758,883Sep 27 08:19 PM
Burow KristinaDirectorSep 25Buy11.2260,740681,4643,724,883Sep 25 09:37 PM
ARCH Venture Partners XII, LLC10% OwnerSep 25Buy11.2260,740681,4643,724,883Sep 25 09:38 PM
ARCH Venture Partners XII, LLC10% OwnerSep 22Buy11.1440,000445,6003,664,143Sep 25 09:38 PM
Burow KristinaDirectorSep 22Buy11.1440,000445,6003,664,143Sep 25 09:37 PM
AMGEN INC10% OwnerSep 19Buy17.001,764,70529,999,98535,368,653Sep 19 07:52 PM
Burow KristinaDirectorSep 19Buy17.001,500,00025,500,0003,624,143Sep 20 06:23 AM
ARCH Venture Partners X, LLC10% OwnerSep 19Buy17.001,500,00025,500,0003,624,143Sep 20 06:16 AM
ARCH Venture Partners X, LLC10% OwnerSep 19Buy17.001,500,00025,500,0003,624,143Sep 20 06:15 AM
Gosebruch Henry OPresident & CEOSep 19Buy12.6215,000189,37015,000Sep 19 09:47 PM
Last Close
Mar 01 04:00PM ET
8.63
Dollar change
+0.18
Percentage change
2.13
%
SLRN Acelyrin Inc daily Stock Chart
IndexRUT P/E- EPS (ttm)- Insider Own37.99% Shs Outstand92.70M Perf Week16.46%
Market Cap839.18M Forward P/E- EPS next Y-4.20 Insider Trans-0.07% Shs Float60.30M Perf Month13.25%
Income- PEG- EPS next Q-1.01 Inst Own71.21% Short Float11.10% Perf Quarter35.69%
Sales- P/S- EPS this Y24.52% Inst Trans- Short Ratio5.99 Perf Half Y-65.00%
Book/sh7.53 P/B1.15 EPS next Y0.11% ROA- Short Interest6.69M Perf Year-
Cash/sh8.11 P/C1.06 EPS next 5Y- ROE- 52W Range5.70 - 29.88 Perf YTD15.68%
Dividend Est.- P/FCF- EPS past 5Y- ROI- 52W High-71.12% Beta-
Dividend TTM- Quick Ratio11.88 Sales past 5Y0.00% Gross Margin- 52W Low51.40% ATR (14)0.53
Dividend Ex-Date- Current Ratio11.88 EPS Y/Y TTM- Oper. Margin- RSI (14)62.07 Volatility7.03% 6.99%
Employees51 Debt/Eq0.00 Sales Y/Y TTM- Profit Margin- Recom1.86 Target Price23.67
Option/ShortYes / Yes LT Debt/Eq0.00 EPS Q/Q-452.98% Payout- Rel Volume0.71 Prev Close8.45
Sales Surprise- EPS Surprise-86.70% Sales Q/Q- EarningsNov 07 AMC Avg Volume1.12M Price8.63
SMA208.69% SMA5015.11% SMA200-39.14% Trades Volume795,560 Change2.13%
Date Action Analyst Rating Change Price Target Change
Dec-13-23Initiated Wells Fargo Equal Weight $11
Dec-08-23Initiated Citigroup Neutral $8
Sep-13-23Downgrade Morgan Stanley Overweight → Equal-Weight $19
Sep-05-23Initiated H.C. Wainwright Buy $44
May-30-23Initiated TD Cowen Outperform
May-30-23Initiated Piper Sandler Overweight $68
May-30-23Initiated Morgan Stanley Overweight
May-30-23Initiated Jefferies Buy $31
Feb-15-24 04:05PM
Jan-10-24 11:30AM
Jan-04-24 09:56AM
Jan-01-24 09:35AM
Dec-27-23 10:45AM
04:30PM Loading…
Dec-20-23 04:30PM
Dec-19-23 12:13AM
Dec-18-23 04:14PM
Dec-12-23 09:25PM
Dec-11-23 09:35AM
Dec-04-23 03:00PM
08:00AM
Nov-30-23 04:30PM
Nov-28-23 05:55PM
01:44PM
07:24AM Loading…
07:24AM
Nov-27-23 09:09PM
04:30PM
Nov-20-23 11:01AM
Nov-16-23 06:42PM
04:11PM
Nov-07-23 05:11PM
04:05PM
Nov-06-23 07:00AM
Oct-31-23 04:30PM
Oct-18-23 09:00PM
Oct-03-23 07:00AM
Sep-15-23 05:39PM
Sep-11-23 04:05PM
Sep-06-23 07:00AM
07:22PM Loading…
Aug-15-23 07:22PM
Aug-14-23 04:05PM
Aug-07-23 04:30PM
Jul-18-23 07:00AM
Jun-15-23 04:05PM
May-09-23 04:10PM
May-05-23 07:08PM
ACELYRIN, Inc. operates as a biopharma company. It engages in identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company was founded by Shao-Lee Lin on July 27, 2020 and is headquartered in Agoura Hills, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Lin Shao-LeeChief Executive OfficerFeb 20Sale7.6015,701119,4031,587,335Feb 22 07:04 PM
Lin Shao-LeeChief Executive OfficerJan 02Sale7.4110,69179,1881,603,036Jan 04 06:09 PM
Westlake BioPartners Fund II, 10% OwnerMay 09Buy18.001,250,00022,500,0009,790,729May 11 09:16 PM
SEIDENBERG BETH CDirectorMay 09Buy18.001,250,00022,500,0009,790,729May 11 09:13 PM
SEIDENBERG BETH CDirectorMay 09Buy18.0060,0001,080,00060,000May 11 09:13 PM
Gosebruch Henry ODirectorMay 09Buy18.0050,000900,00050,000May 11 09:06 PM
Svoronos DawnDirectorMay 09Buy18.0015,000270,00015,000May 11 09:11 PM
Peloso PaulChief Medical OfficerMay 09Buy18.006,000108,0006,000May 11 08:54 PM
Dier MardiCFO and CBOMay 09Buy18.005,556100,0085,556May 11 08:51 PM
Kim MinaChief Legal & Admin. OfficerMay 09Buy18.005,00090,0005,000May 11 08:58 PM
Becker Daniel J.DirectorMay 09Buy18.003,00054,0003,000May 11 09:02 PM
Dier MardiCFO and CBOMay 09Buy18.001,75031,500875May 11 08:51 PM
Oyston RonaldChief People OfficerMay 09Buy18.001,00018,0001,000May 11 09:00 PM
Oyston RonaldChief People OfficerMay 09Buy18.002646826May 11 09:00 PM
Last Close
Mar 01 04:00PM ET
178.91
Dollar change
+2.86
Percentage change
1.62
%
ABBV Abbvie Inc daily Stock Chart
IndexS&P 500 P/E65.77 EPS (ttm)2.72 Insider Own0.15% Shs Outstand1.77B Perf Week0.46%
Market Cap316.04B Forward P/E14.68 EPS next Y12.19 Insider Trans-10.36% Shs Float1.76B Perf Month8.83%
Income4.82B PEG20.07 EPS next Q2.37 Inst Own71.99% Short Float0.84% Perf Quarter29.18%
Sales54.32B P/S5.82 EPS this Y0.57% Inst Trans0.10% Short Ratio2.71 Perf Half Y20.62%
Book/sh5.87 P/B30.50 EPS next Y9.07% ROA3.52% Short Interest14.75M Perf Year15.23%
Cash/sh7.26 P/C24.66 EPS next 5Y3.28% ROE34.90% 52W Range130.96 - 179.89 Perf YTD15.45%
Dividend Est.6.23 (3.48%) P/FCF14.35 EPS past 5Y-5.77% ROI7.61% 52W High-0.54% Beta0.56
Dividend TTM5.99 (3.35%) Quick Ratio0.76 Sales past 5Y11.76% Gross Margin70.40% 52W Low36.61% ATR (14)2.87
Dividend Ex-DateApr 12, 2024 Current Ratio0.87 EPS Y/Y TTM-59.03% Oper. Margin37.04% RSI (14)67.44 Volatility1.52% 1.86%
Employees50000 Debt/Eq5.80 Sales Y/Y TTM-6.44% Profit Margin8.87% Recom1.89 Target Price180.38
Option/ShortYes / Yes LT Debt/Eq5.11 EPS Q/Q-67.09% Payout220.33% Rel Volume0.74 Prev Close176.05
Sales Surprise1.97% EPS Surprise-0.11% Sales Q/Q-5.42% EarningsFeb 02 BMO Avg Volume5.44M Price178.91
SMA202.32% SMA507.61% SMA20019.59% Trades Volume4,028,546 Change1.62%
Date Action Analyst Rating Change Price Target Change
Jan-29-24Upgrade William Blair Mkt Perform → Outperform
Dec-18-23Downgrade HSBC Securities Buy → Hold
Dec-11-23Upgrade Goldman Neutral → Buy
Nov-09-23Initiated Deutsche Bank Hold $150
Oct-30-23Upgrade Barclays Equal Weight → Overweight $160 → $170
Oct-20-23Resumed UBS Neutral $157 → $150
Sep-29-23Initiated Raymond James Outperform $177
Jul-25-23Initiated William Blair Mkt Perform
Jul-14-23Initiated HSBC Securities Buy $167
Apr-05-23Downgrade Argus Buy → Hold
Mar-01-24 11:35PM
05:45PM
10:12AM
09:00AM
Feb-29-24 09:45AM
08:00AM Loading…
08:00AM
Feb-28-24 02:02PM
11:05AM
10:17AM
09:36AM
05:27AM
12:05AM
Feb-27-24 09:23AM
08:00AM
08:00AM
07:45AM Loading…
07:45AM
07:45AM
05:45AM
Feb-26-24 07:45PM
07:20AM
Feb-24-24 03:00PM
07:04AM
Feb-22-24 04:48PM
09:11AM
08:05AM
05:15AM
Feb-21-24 06:41PM
06:02PM
05:39PM
11:45AM
10:43AM Loading…
10:43AM
09:12AM
08:00AM
12:02AM
Feb-20-24 12:48PM
11:21AM
10:18AM
09:17AM
09:05AM
09:00AM
07:00AM
04:52AM
Feb-19-24 10:15AM
09:00AM
08:30AM
Feb-17-24 01:29PM
Feb-15-24 12:03PM
08:45AM
Feb-14-24 02:02PM
Feb-13-24 06:02AM
Feb-12-24 12:18PM
07:37AM
07:30AM
Feb-11-24 08:25AM
Feb-10-24 08:30AM
Feb-08-24 08:00AM
Feb-07-24 10:13AM
Feb-06-24 01:53PM
12:00PM
09:00AM
09:00AM
06:01AM
Feb-05-24 07:37PM
06:55PM
04:00PM
02:58PM
11:45AM
08:54AM
07:00AM
Feb-04-24 06:24PM
05:50AM
Feb-03-24 08:12AM
03:56AM
Feb-02-24 03:47PM
03:45PM
02:41PM
01:12PM
01:04PM
12:12PM
12:08PM
11:27AM
11:08AM
10:00AM
08:45AM
08:16AM
08:12AM
07:43AM
07:39AM
07:36AM
07:36AM
Jan-31-24 11:00AM
Jan-30-24 03:57PM
01:50PM
09:15AM
07:59AM
Jan-29-24 05:45PM
04:09PM
04:00PM
Jan-28-24 11:42AM
Jan-26-24 10:00AM
AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Michael Robert A.PRES & CHIEF OPERATING OFFICERFeb 29Option Exercise58.3021,5601,257,012167,524Mar 01 05:50 PM
Michael Robert A.PRES & CHIEF OPERATING OFFICERFeb 29Sale176.4568,87912,153,95798,645Mar 01 05:50 PM
Siatis Perry CEVP, GC AND SECRETARYFeb 29Sale177.399,8911,754,55510,397Mar 01 05:50 PM
Buckbee Kevin KSVP, CONTROLLERFeb 29Sale176.655,144908,6886,983Mar 01 05:50 PM
GONZALEZ RICHARD ACHAIRMAN OF THE BOARD AND CEOFeb 28Sale177.27138,61624,572,458519,099Mar 01 05:50 PM
Siatis Perry CEVP, GC AND SECRETARYFeb 23Option Exercise137.3613,7531,889,11541,926Feb 27 05:10 PM
Reents Scott TEVP, CHIEF FINANCIAL OFFICERFeb 23Option Exercise61.3614,140867,63041,205Mar 01 05:50 PM
Reents Scott TEVP, CHIEF FINANCIAL OFFICERFeb 23Sale177.4414,1402,509,00227,065Mar 01 05:50 PM
Siatis Perry CEVP, GC AND SECRETARYFeb 23Sale177.5113,7532,441,29528,173Feb 27 05:10 PM
SALEKI-GERHARDT AZITAEVP, CHIEF OPERATIONS OFFICERFeb 21Option Exercise58.8852,8703,112,986296,814Feb 23 05:00 PM
SALEKI-GERHARDT AZITAEVP, CHIEF OPERATIONS OFFICERFeb 21Sale173.7152,8709,184,048243,944Feb 23 05:00 PM
Donoghoe NicholasEVP, CHIEF BUS/STRAT OFFICERDec 26Sale154.722,912450,54555,903Dec 28 05:00 PM
GONZALEZ RICHARD ACHAIRMAN OF THE BOARD AND CEOAug 01Sale148.5860,0008,914,800565,294Aug 02 05:07 PM
GONZALEZ RICHARD ACHAIRMAN OF THE BOARD AND CEOJul 31Sale149.1518,5002,759,275625,294Aug 02 05:07 PM
Sorg Elaine K.SVP, US COMMERCIAL OPERATIONSApr 25Option Exercise144.546,130886,03041,460Apr 27 05:00 PM
Sorg Elaine K.SVP, US COMMERCIAL OPERATIONSApr 25Sale165.006,1301,011,45035,330Apr 27 05:00 PM
Sorg Elaine K.SVP, US COMMERCIAL OPERATIONSApr 17Sale161.677,4991,212,33835,330Apr 19 05:00 PM
Sorg Elaine K.SVP, US COMMERCIAL OPERATIONSApr 03Option Exercise93.5015,0021,402,68757,831Apr 05 05:00 PM
Siatis Perry CEVP, GC AND SECRETARYApr 03Option Exercise105.923,520372,83813,897Apr 05 05:00 PM
Sorg Elaine K.SVP, US COMMERCIAL OPERATIONSApr 03Sale160.0315,0022,400,77042,829Apr 05 05:00 PM
Siatis Perry CEVP, GC AND SECRETARYApr 03Sale160.003,520563,20010,377Apr 05 05:00 PM
Stewart Jeffrey RyanEVP, CHIEF COMMERCIAL OFFICERMar 13Option Exercise54.8621,8101,196,497114,066Mar 15 05:00 PM
Stewart Jeffrey RyanEVP, CHIEF COMMERCIAL OFFICERMar 13Sale152.2853,1258,089,99860,941Mar 15 05:00 PM